Adverse effects of antidepressant use in pregnancy: An evaluation of fetal growth and preterm birth

The Motherisk Program, The Hospital for Sick Children, Toronto, Canada.
Depression and Anxiety (Impact Factor: 4.41). 01/2010; 27(1):35-8. DOI: 10.1002/da.20598
Source: PubMed


To compare the rates of low birth weight, preterm delivery and small for gestational age (SGA), in pregnancy outcomes among women who were exposed and nonexposed to antidepressants during pregnancy.
At The Motherisk Program, we analyzed pregnancy outcomes of 1,243 women in our database who took various antidepressants during their pregnancy. Nine hundred and twenty-eight of these women and 928 nonexposed women who delivered a live born infant were matched for age, (+/-2 years), smoking and alcohol use and specific pregnancy outcomes were compared between the two groups.
There were 82 (8.8%) preterm deliveries in the antidepressant group and 50 (5.4%) in the comparison group. OR: 1.7 (95% CI: 1.18-2.45). There were 89 (9.6%) in the antidepressant group and 76 (8.2%) in the comparison group who delivered babies evaluated as SGA; OR: 1.19 (95% CI: 0.86-1.64). The mean birth weight in the antidepressant group was 3,449+/-591 g and 3,455+/-515 g in the comparison group (P=.8).
The use of antidepressants in pregnancy appears to be associated with a small, but statistically significant increased rate in the incidence of preterm births, confirming results from several other studies. It is difficult to ascertain whether this small increased rate of preterm births is confounded by depression, antidepressants, or both. However, we did not find a statistically significant difference in the incidence of SGA or lower birth weight. This information adds to limited data available in the literature regarding these outcomes following the use of antidepressants in pregnancy.

1 Follower
16 Reads
  • Source
    • "With regard to premature delivery as a discrete outcome, observational studies have documented an increased risk associated with antenatal antidepressant exposure.87,162–165 However, not all studies are in agreement,89,90,92,100,166,167 and one study even documented a reduced risk of spontaneous preterm birth associated with medication treatment of depressive symptoms during pregnancy, although the main exposure group included both sedative medications and antidepressants.32 Most studies to date have focused on antenatal SSRI use; however, an increased risk of preterm delivery has also been reported for TCAs, venlafaxine, and mirtazapine.97,127,128 "
    [Show abstract] [Hide abstract]
    ABSTRACT: In pregnant women with major depression, the overarching goal of treatment is to achieve or maintain maternal euthymia, thus limiting both maternal and fetal exposure to the harmful effects of untreated or incompletely treated depression. However, the absence of uniformly effective therapies with guaranteed obstetric and fetal safety makes the treatment of major depression during pregnancy among the most formidable of clinical challenges. Clinicians and patients are still faced with conflicting data and expert opinion regarding the reproductive safety of antidepressants in pregnancy, as well as large gaps in our understanding of the effectiveness of most antidepressants and nonpharmacological alternatives for treating antenatal depression. In this paper, we provide a clinically focused review of the available information on potential maternal and fetal risks of untreated maternal depression during pregnancy, the effectiveness of interventions for maternal depression during pregnancy, and potential obstetric, fetal, and neonatal risks associated with antenatal antidepressant use.
    Drug, Healthcare and Patient Safety 09/2014; 6:109-29. DOI:10.2147/DHPS.S43308
  • Source
    • "7 Yes Roca [21] 2011 SSRI Nondepressed Retrospective 252 1.37 (0.46–3.81) 3.44 (1.30–9.11) 7 No Einarson [22] 2010 Various AD Nondepressed Retrospective 1856 1.7 (1.18–2.45) 6 No Lewis [23] 2010 SSRI or SNRI Mixed Prospective 54 8.33 (1.11–62.67) "
    General hospital psychiatry 01/2014; 36(3). DOI:10.1016/j.genhosppsych.2014.01.005 · 2.61 Impact Factor
  • Source
    • "7 Yes Roca [21] 2011 SSRI Nondepressed Retrospective 252 1.37 (0.46–3.81) 3.44 (1.30–9.11) 7 No Einarson [22] 2010 Various AD Nondepressed Retrospective 1856 1.7 (1.18–2.45) 6 No Lewis [23] 2010 SSRI or SNRI Mixed Prospective 54 8.33 (1.11–62.67) "
    [Show abstract] [Hide abstract]
    ABSTRACT: To examine the relationship between antidepressant use in pregnancy and low birth weight (LBW) and preterm birth (PTB). We searched English and non-English language articles via PubMed, CINAHL and PsychINFO (from their start dates through December 1st, 2012). We used the following keywords and their combinations: antidepressant, selective serotonin reuptake inhibitor (SSRI), pregnancy, antenatal, prenatal, birthweight, birth weight, preterm, prematurity, gestational age, fetal growth restriction, intrauterine growth restriction, and small-for-gestational age. Published studies were considered eligible if they examined exposure to antidepressant medication use during pregnancy and reported data on at least one birth outcome of interest: PTB (<37 weeks gestation) or LBW (<2500 g). Of the 222 reviewed studies, 28 published studies met the selection criteria. Two authors independently extracted study characteristics from eligible studies. Using random-effects models, antidepressant use in pregnancy was significantly associated with LBW (RR: 1.44, 95% confidence interval (CI): 1.21-1.70) and PTB (RR: 1.69, 95% CI: 1.52-1.88). Studies varied widely in design, populations, control groups and methods. There was a high level of heterogeneity as measured by I2 statistics for both outcomes examined. The relationship between antidepressant exposure in pregnancy and adverse birth outcomes did not differ significantly when taking into account drug type (SSRI vs. other or mixed) or study design (prospective vs. retrospective). There was a significant association between antidepressant exposure and PTB for different types of control status used (depressed, mixed or nondepressed). Antidepressant use during pregnancy significantly increases the risk for LBW and PTB.
    General hospital psychiatry 10/2013; 36(1). DOI:10.1016/j.genhosppsych.2013.08.002 · 2.61 Impact Factor
Show more